Investigational New Drugs

A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells
pp. 523-533(11)
Authors: Shahabuddin, M.; Nambiar, Mridula; Moorthy, Balaji; Naik, Prakruthi; Choudhary, Bibha; Advirao, Gopal; Raghavan, Sathees

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo
pp. 534-543(10)
Authors: Hirai, Hiroshi; Takahashi-Suziki, Ikuko; Shimomura, Toshiyasu; Fukasawa, Kazuhiro; Machida, Takumitsu; Takaki, Toru; Kobayashi, Makiko; Eguchi, Tomohiro; Oki, Hiroko; Arai, Tsuyoshi; Ichikawa, Koji; Hasako, Shinichi; Kodera, Tsutomu; Kawanishi, Nobuhiko; Nakatsuru, Yoko; Kotani, Hidehito; Iwasawa, Yoshikazu

Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells
pp. 544-553(10)
Authors: Wilmes, Anja; Rawson, Pisana; Peng, Lifeng; McLauchlan, Danyl; Northcote, Peter; Jordan, T.; Miller, John

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo
pp. 554-561(8)
Authors: Torres, Mylin; Raju, Uma; Molkentine, David; Riesterer, Oliver; Milas, Luka; Ang, K.

Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism
pp. 562-573(12)
Authors: Hoyt, Mirth; Palchaudhuri, Rahul; Hergenrother, Paul

LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin
pp. 574-582(9)
Authors: Gao, Jian-Jun; Gao, Zu-Hua; Zhao, Cui-Rong; Yuan, Yi; Cui, Shu-Xiang; Zhang, Xiao-Fan; Cheng, Yan-Na; Xu, Wen-Fang; Tang, Wei; Qu, Xian-Jun

A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells
pp. 583-592(10)
Authors: Chiruvella, Kishore; Raghavan, Sathees

The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats
pp. 593-606(14)
Authors: Deng, Meihong; Huang, Hai; Jin, Hao; Dirsch, Olaf; Dahmen, Uta

Anticancer activity and mode of action of titanocene C
pp. 607-614(8)
Authors: Olszewski, Ulrike; Claffey, James; Hogan, Megan; Tacke, Matthias; Zeillinger, Robert; Bednarski, Patrick; Hamilton, Gerhard

Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF7
pp. 615-626(12)
Authors: Chan, Ariane; Andreae, Peter; Northcote, Peter; Miller, John

Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest
pp. 627-636(10)
Authors: Fu, Jia-ning; Li, Jing; Tan, Qiang; Yin, Han-wei; Xiong, Kun; Wang, Tian-yu; Ren, Xiao-yuan; Zeng, Hui-hui

Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo
pp. 637-645(9)
Authors: Xu, Xiao-Fang; Cai, Bo-Lei; Guan, Su-Min; Li, Yan; Wu, Jun-Zheng; Wang, Yong; Liu, Bin

B1, a novel naphthalimide-based DNA intercalator, induces cell cycle arrest and apoptosis in HeLa cells via p53 activation
pp. 646-658(13)
Authors: Liang, Xin; Wu, Aibin; Xu, Yufang; Xu, Ke; Liu, Jianwen; Qian, Xuhong

Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line
pp. 659-665(7)
Authors: Takahashi, Yuuka; Hazawa, Masaharu; Takahashi, Kenji; Nishizawa, Ayumi; Yoshizawa, Atsushi; Kashiwakura, Ikuo

Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21
pp. 666-673(8)
Authors: Zhang, Yongci; Yang, Ming; Ji, Qing; Fan, Dongmei; Peng, Hui; Yang, Chunzheng; Xiong, Dongsheng; Zhou, Yuan

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α_v integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer
pp. 674-679(6)
Authors: Chu, Franklin; Picus, Joel; Fracasso, Paula; Dreicer, Robert; Lang, Zhihui; Foster, Brenda

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study
pp. 680-687(8)
Authors: Ho, Cheryl; Sangha, Randeep; Beckett, Laurel; Tanaka, Michael; Lau, Derick; Eisen, Daniel; Burich, Rachel; Luciw, Paul; Khan, Imran; Mack, Philip; Gandara, David; Davies, Angela

Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
pp. 688-693(6)
Authors: Shitara, Kohei; Yokota, Tomoya; Takahari, Daisuke; Shibata, Takashi; Ura, Takashi; Utsunomiya, Setsuo; Inaba, Yoshitaka; Yamaura, Hidekazu; Sato, Yozo; Najima, Mina; Kawai, Hiroki; Tajika, Masahiro; Sawaki, Akira; Yatabe, Yasushi; Muro, Kei

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
pp. 694-699(6)
Authors: El-Rayes, Bassel; Philip, Philip; Sarkar, Fazlul; Shields, Anthony; Ferris, Ann; Hess, Kenneth; Kaseb, Ahmad; Javle, Milind; Varadhachary, Gauri; Wolff, Robert; Abbruzzese, James

Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients
pp. 700-705(6)
Authors: Leroy, Tanguy; Christophe, Véronique; Penel, Nicolas; Antoine, Pascal; Clisant, Stéphanie

The notorious “drug lag“ for oncology drugs in Japan
pp. 706-712(7)
Authors: Yonemori, Kan; Hirakawa, Akihiro; Ando, Masashi; Hirata, Taizo; Yunokawa, Mayu; Shimizu, Chikako; Katsumata, Noriyuki; Tamura, Kenji; Fujiwara, Yasuhiro

Proposal for size justification of expanded cohort at phase-2-recommended dose
pp. 713-715(3)
Authors: Penel, Nicolas; Fournier, Charles; Bérille, Jocelyne

Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents
pp. 716-718(3)
Authors: Mir, Olivier; Coriat, Romain; Gregory, Thomas; Ropert, Stanislas; Billemont, Bertrand; Goldwasser, François